Tom Lee's Fund Analyst: Bitcoin Could Fall to $60,000 to $65,000 and Ethereum to $1,800 to $2,000 in the First Half of 2026
BlockBeats News, December 20th, Fundstrat's Cryptocurrency Strategy Director Sean Farrell, under the umbrella of Tom Lee, stated in the "2026 Cryptocurrency Outlook" report, "While I believe that Bitcoin and the entire crypto market still have strong long-term bullish factors, and the support driven by liquidity is expected to emerge in 2026, we may still need to digest several risks in the first/second quarter of 2026, which may bring more attractive entry points."
My baseline assessment is: a more obvious decline will occur in the first half of 2026. Bitcoin may fall to $60,000–$65,000, Ethereum may fall to $1,800–$2,000, and SOL may fall to $50–$75. These price levels will provide better opportunities for positioning before the end of the year. If this assessment proves to be incorrect, I still lean towards maintaining a defensive posture, waiting for confirmation signals of a strengthening trend. Bitcoin's year-end target is around $115,000, and Ethereum's year-end target may reach $4,500.
In this framework, the relative strength of ETH will be more pronounced. I believe this is reasonable, as Ethereum has more favorable structural fund flow characteristics, including: no miner selling pressure, unaffected by factors related to MSTR, and relatively lower concerns about quantum risk."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.
The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).
China’s gold imports exceeded 1,000 tons by August, surpassing the total for all of 2025.

